🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

14 recruiting trials

for Unresectable Locally Recurrent Breast Cancer

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer NCT07461454Phase 31 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202, Eribulin, Capecitabine, Gemcitabine, Vinorelbine A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer NCT07497386Phase 21 site📍 Beijing Jiangsu HengRui Medicine Co., Ltd. · Tests: Trastuzumab Rezetecan for Injection, Trastuzumab Deruxtecan for Injection Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer NCT06324240Phase 14 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Ipilimumab, Pembrolizumab, Vaccine Therapy Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354Phase 3283 sites📍 Mobile📍 Chandler📍 Duarte Merck Sharp & Dohme LLC · Tests: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959Phase 31 site📍 Beijing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer NCT06993506n/a19 sites📍 Hefei📍 Beijing📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: SKB264 Monotherapy or Combination Therapy A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer NCT07111832Phase 32 sites📍 Beijing📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1811 for Injection, SHR-1316 Injection, Toripalimab Injection, Paclitaxel for Injection Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377Phase 2484 sites📍 Birmingham📍 Mobile📍 Anchorage National Cancer Institute (NCI) · Tests: Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer NCT06042894Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, SI-B003 A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care NCT07533123Phase 31 site📍 Guangzhou Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Tests: JSKN016 Injection, Eribulin Mcsilate Injection, Vinorelbine Tartrate Injection, Capecitabine Tablets, Gemcitabine Hydro…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy